程序性坏死(Necroptosis)的分子机制

程序性坏死(Necroptosis)是一种不同于凋亡及传统坏死的细胞程序性死亡方式, 可由肿瘤坏死因子受体(Tumor necrosis factor receptor, TNFR)或模式识别受体(Pattern recognition receptor, PRR)调控启动。受体相互作用蛋白(Receptor-interacting protein, RIP)1和3是启动necroptosis的两个关键蛋白, necroptosis启动后需要一系列分子传递和执行死亡信号, 如多核苷酸二磷酸-核糖聚合酶-1(Poly(ADP-ribose) polymerase, PARP-1)、活性氧簇(Reactive oxygen species, ROS)、Ca²⁺等, 这些分子破坏线粒体及其他细胞器, 最终使细胞在缺乏天冬氨酸半胱氨酸蛋白酶(Caspase)的情况下死亡。Necroptosis细胞可将损伤相关模式分子(Damage-associated molecular patterns, DAMPs)暴露到细胞外, 被吞噬细胞识别并清除。文章对启动necroptosis的受体分子、传递执行细胞坏死的重要分子和坏死细胞的清除过程进行了概述。     

Necroptosis的调控机制及其在组织及细胞缺血损伤中的作用和意义

Necroptosis不同于坏死和凋亡,具有坏死的细胞形态特点和自噬的活化,并且是主动耗能的,是被一系列信号传导通路所调控的细胞死亡机制。Necroptosis的发现和确认为细胞死亡的逆转和治疗开创了一个新的研究和应用途经。RIPl激酶是调控Necroptosis形成的关键酶,Necrostatins则是一类小分子化合物,它通过特异性地抑制细胞RIPl激酶而抑制Necroptosis的形成。     

程序性坏死与心脑血管疾病

程序性坏死(necroptosis)是一种新型的细胞程序性死亡类型,受细胞内信号因子的调控,但同细胞凋亡有着显著区别。程序性坏死的发生需要一系列分子传递和执行死亡信号,受体相互作用蛋白激酶RIP1和RIP3是关键的调控因子。这种细胞死亡模式在心脑血管疾病的病理过程中起着非常重要的作用。     

mTOR信号通路在疾病中的作用与调控机制

mTOR是一种丝氨酸/苏氨酸蛋白激酶,与不同的蛋白质结合形成mTORC1和mTORC2两种复合物,体现了结构和功能上的差异。mTOR信号通路参与多种生理和病理过程,不仅可以调节细胞生长、代谢、血管生成、内环境稳定、自噬和衰老等生理过程,还与多种恶性肿瘤、自身免疫性疾病、心脑血管疾病等一系列的疾病发生及肿瘤抗药性相关。该文综述了mTOR信号通路在疾病发生中的作用及调控机制,为疾病治疗提供参考。     

MAPK/ERK 和 MAPK/P38 信号通路的活化参与沙眼衣原体诱导前炎因子的产生

沙眼衣原体感染可导致沙眼、性传播性疾病、不孕症等疾病,主要病理表现是炎症反应引起的组织损伤和瘢痕.因此,沙眼衣原体诱导产生的炎症因子是导致疾病的关键,沙眼衣原体可直接感染内皮细胞产生各种前炎因子,但其机制目前还不清楚.通过ELISA和免疫印迹等方法,检测到沙眼衣原体感染HeLa229细胞可产生IL-8,IL-1α,IL-1β,IL-6等前炎因子,并且沙眼衣原体感染可以主要激活宿主细胞MAPK/ERK和MAPK/P38信号通路.抑制MAPK/ERK和MAPK/P38信号通路显示,两条通路在沙眼衣原体感染过程中参与调节不同的炎症因子产生.MAPK/P38信号通路的活化参与调控IL-1α,IL-6的产生,而IL-8则同时受MAPK/ERK和MAPK/P38两条通路的调控.     

β-拘留蛋白2的活性调控机制

β-拘留蛋白2(β-arrestin2)是arrestins家族的一个成员,广泛表达于全身组织,其不仅可以调节大多数G蛋白偶联受体(G-protein coupled receptors, GPCRs)的脱敏、内化,还能调节多种非GPCRs的内化,或作为支架蛋白质参与MAPK、PI3K/AKT等信号通路。越来越多的研究发现,β-arrestin2在肿瘤、自身免疫性疾病、纤维化疾病、心血管疾病、代谢性疾病等多种疾病进展过程中表达异常,提示其可能在疾病的病理过程中发挥重要的调控作用。β-arrestin2功能的发挥不仅与其在细胞中的表达水平有关,更依赖于对其活性的调控。但对于β-arrestin2的活性如何被调控,以及其活性如何影响其生物学功能的关注较少。近年来,陆续有研究报道了β-arrestin2可发生磷酸化、泛素化、SUMO化、S-亚硝基化等翻译后修饰,探讨了其翻译后修饰的可能位点,并发现翻译后修饰可影响β-arrestin2的细胞定位、调节受体内吞的作用、β-arrestin2与信号分子的相互作用及下游信号通路,对了解β-arrestin2活性调控在细胞中的作用具有重要意义。本文在...     

高迁移率族蛋白B1的胞外作用与免疫效应

高迁移率族蛋白B1(HMGB1)是一种高度保守的核蛋白,具有调控DNA稳定、复制、转录及翻译等功能.近年来的研究表明,它通过主动或被动的方式被释放至细胞外,并作为一种晚期炎症介质,参与脓毒症等炎症性疾病的发病过程,同时也可作为一种免疫"预警信号"调控机体免疫反应.本文综述了HMGB1的结构、分泌机制、受体信号通路及其对细胞免疫的调控作用.     

MST1/2调控先天免疫的功能和机制

Hippo信号通路通过一系列激酶级联反应,实现对细胞增殖、器官大小以及组织再生等方面的调控。其中,MST1/2是核心激酶Hippo蛋白在哺乳动物中的同源物,对于下游信号通路的激活至关重要。此外,MST1/2在细胞分化、形态和细胞骨架重排等方面也发挥重要作用。近期多项研究工作指出,MST1/2参与调控免疫T细胞的粘附、迁移、归巢和抑制性Treg细胞的成熟与功能,以及心肌细胞自噬等过程。有趣的是,这一功能是不依赖经典的Hippo信号通路的,被称为“非经典Hippo信号通路”。最新的研究结果揭示了MST1/2通过非经典Hippo信号通路调控先天免疫巨噬细胞对病原菌或病毒的免疫应答,包括巨噬细胞的吞噬、细胞因子(炎症因子、趋化因子、Ⅰ型干扰素等)和线粒体活性氧的产生,从而在机体抵抗细菌病毒感染、炎症相关癌症、动脉粥样硬化等疾病中发挥重要功能。本文对MST1/2调控先天免疫功能、相关分子机制和疾病进行了总结和讨论。     

Wnt/β-catenin信号通路及其在心脏疾病中的作用

Wnt/β-catenin信号通路是以调控β-catenin的稳定性和核定位为核心过程的经典Wnt通路,在细胞增殖、分化和组织稳态维持过程中发挥重要作用.许多细胞外基质蛋白、生长因子等参与该通路的上游调控,此外其他信号通路可以通过与其相互作用精确调控细胞生理功能.在心脏中该通路的异常激活是导致心肌肥厚和心肌损伤的病理生...     

The regulation of necroptosis by ubiquitylation

Necroptosis is a programmed necrosis that is mediated by receptor-interacting protein kinases RIPK1, RIPK3 and the mixed lineage kinase domain-like protein, MLKL. Necroptosis must be strictly regulated to maintain normal tissue homeostasis, and dysregulation of necroptosis leads to the development of various inflammatory, infectious, and degenerative diseases. Ubiquitylation is a widespread post-translational modification that is essential for balancing numerous physiological processes. Over the past decade, considerable progress has been made in the understanding of the role of ubiquitylation in regulating necroptosis. Here, we will discuss the regulatory functions of ubiquitylation in necroptosis signaling pathway. An enhanced understanding of the ubiquitylation enzymes and regulatory proteins in necroptotic signaling pathway will be exploited for the development of new therapeutic strategies for necroptosis-related diseases.

     

Staurosporine Induces Necroptotic Cell Death under Caspase-Compromised Conditions in U937 Cells

For a long time necrosis was thought to be an uncontrolled process but evidences recently have revealed that necrosis can also occur in a regulated manner. Necroptosis, a type of programmed necrosis is defined as a death receptor-initiated process under caspase-compromised conditions. The process requires the kinase activity of receptor-interacting protein kinase 1 and 3 (RIPK1 and RIPK3) and mixed lineage kinase domain-like protein (MLKL), as a substrate of RIPK3. The further downstream events remain elusive. We applied known inhibitors to characterize the contributing enzymes in necroptosis and their effect on cell viability and different cellular functions were detected mainly by flow cytometry. Here we report that staurosporine, the classical inducer of intrinsic apoptotic pathway can induce necroptosis under caspase-compromised conditions in U937 cell line. This process could be hampered at least partially by the RIPK1 inhibitor necrotstin-1 and by the heat shock protein 90 kDa inhibitor geldanamycin. Moreover both the staurosporine-triggered and the classical death ligand-induced necroptotic pathway can be effectively arrested by a lysosomal enzyme inhibitor CA-074-OMe and the recently discovered MLKL inhibitor necrosulfonamide. We also confirmed that the enzymatic role of poly(ADP-ribose)polymerase (PARP) is dispensable in necroptosis but it contributes to membrane disruption in secondary necrosis. In conclusion, we identified a novel way of necroptosis induction that can facilitate our understanding of the molecular mechanisms of necroptosis. Our results shed light on alternative application of staurosporine, as a possible anticancer therapeutic agent. Furthermore, we showed that the CA-074-OMe has a target in the signaling pathway leading to necroptosis. Finally, we could differentiate necroptotic and secondary necrotic processes based on participation of PARP enzyme.     

Myofiber necroptosis promotes muscle stem cell proliferation via releasing Tenascin-C during regeneration

Necroptosis, a form of programmed cell death, is characterized by the loss of membrane integrity and release of intracellular contents, the execution of which depends on the membrane-disrupting activity of the Mixed Lineage Kinase Domain-Like protein (MLKL) upon its phosphorylation. Here we found myofibers committed MLKL-dependent necroptosis after muscle injury. Either pharmacological inhibition of the necroptosis upstream kinase Receptor Interacting Protein Kinases 1 (RIPK1) or genetic ablation of MLKL expression in myofibers led to significant muscle regeneration defects. By releasing factors into the muscle stem cell (MuSC) microenvironment, necroptotic myofibers facilitated muscle regeneration. Tenascin-C (TNC), released by necroptotic myofibers, was found to be critical for MuSC proliferation. The temporary expression of TNC in myofibers is tightly controlled by necroptosis; the extracellular release of TNC depends on necroptotic membrane rupture. TNC directly activated EGF receptor (EGFR) signaling pathway in MuSCs through its N-terminus assembly domain together with the EGF-like domain. These findings indicate that necroptosis plays a key role in promoting MuSC proliferation to facilitate muscle regeneration.Subject terms: Necroptosis, Muscle stem cells     

坏死性凋亡在细菌与宿主相互作用中的机制研究进展

坏死性凋亡(necroptosis)是由受体相互作用蛋白(receptor-interacting protein/receptor-interacting protein kinase,RIP/RIPK)调控的调节性细胞死亡(regulated cell death,RCD)方式之一,可分为依赖RIPK1的经典途径和不依赖RIPK1的非经典途径。RIPK3和混合系列激酶结构域样蛋白(mixed lineage kinase domain-like,MLKL)通过以上两种途径被有序激活,最终诱导细胞发生坏死性凋亡。病原微生物感染过程中会发生多种形式的细胞死亡,其结局高度依赖宿主受感染细胞的命运,一方面细菌毒力因子导致宿主细胞发生坏死性凋亡;另一方面坏死性凋亡也是宿主免疫防御的重要方式。深入探讨坏死性凋亡在细菌与宿主相互作用中的机制对揭示感染性疾病的发生和发展具有重要意义。     

Repurposing anticancer drugs for targeting necroptosis

Necroptosis represents a form of programmed cell death that can be engaged by various upstream signals, for example by ligation of death receptors, by viral sensors or by pattern recognition receptors. It depends on several key signaling proteins, including the kinases Receptor-Interacting Protein (RIP)1 and RIP3 and the pseudokinase mixed-lineage kinase domain-like protein (MLKL). Necroptosis has been implicated in a number of physiological and pathophysiological conditions and is disturbed in many human diseases. Thus, targeted interference with necroptosis signaling may offer new opportunities for the treatment of human diseases. Besides structure-based drug design, in recent years drug repositioning has emerged as a promising alternative to develop drug-like compounds. There is accumulating evidence showing that multi-targeting kinase inhibitors, for example Dabrafenib, Vemurafenib, Sorafenib, Pazopanib and Ponatinib, used for the treatment of cancer also display anti-necroptotic activity. This review summarizes recent evidence indicating that some anticancer kinase inhibitors also negatively affect necroptosis signaling. This implies that some cancer therapeutics may be repurposed for other pathologies, e.g. ischemic or inflammatory diseases.     

Post-translational modifications as key regulators of TNF-induced necroptosis

Necroptosis is a novel form of programmed cell death that is independent of caspase activity. Different stimuli can trigger necroptosis. At present, the most informative studies about necroptosis derive from the tumor necrosis factor (TNF)-triggered system. The initiation of TNF-induced necroptosis requires the kinase activity of receptor-interacting protein 1 and 3 (RIP1 and RIP3). Evidence now reveals that the ability of RIP1 and RIP3 to modulate this key cellular event is tightly controlled by post-translational modifications, including ubiquitination, phosphorylation, caspase 8-mediated cleavage and GlcNAcylation. These regulatory events coordinately determine whether a cell will survive or die by apoptosis or necroptosis. In this review, we highlight recent advances in the study of post-translational modifications during TNF-induced necroptosis and discuss how these modifications regulate the complex and delicate control of programmed necrosis.     

The role of necroptosis in cancer: A double-edged sword?

Necroptosis is a programmed, caspase-independent cell death that is morphologically similar to necrosis. Unlike apoptosis, necroptosis evokes inflammatory responses by releasing damage-associated molecular patterns. Recent studies suggest that tumor undergoes necroptosis in vivo and necroptosis has pro- or anti-tumoral effects in cancer development and progression. Furthermore, triggering necroptosis in tumor cells has been explored as a potential therapeutic strategy against cancer. Here, we will review the recent research progress of necroptosis in conferring anti- or pro-tumoral effects and its potential application in cancer therapy.     

Necrosis and necroptosis in germ cell depletion from mammalian ovary

The maximum number of germ cells is present during the fetal life in mammals. Follicular atresia results in rapid depletion of germ cells from the cohort of the ovary. At the time of puberty, only a few hundred (<1%) germ cells are either culminated into oocytes or further get eliminated during the reproductive life. Although apoptosis plays a major role, necrosis as well as necroptosis, might also be involved in germ cell elimination from the mammalian ovary. Both necrosis and necroptosis show similar morphological features and are characterized by an increase in cell volume, cell membrane permeabilization, and rupture that lead to cellular demise. Necroptosis is initiated by tumor necrosis factor and operated through receptor interacting protein kinase as well as mixed lineage kinase domain-like protein. The acetylcholinesterase, cytokines, starvation, and oxidative stress play important roles in necroptosis-mediated granulosa cell death. The granulosa cell necroptosis directly or indirectly induces susceptibility toward necroptotic or apoptotic cell death in oocytes. Indeed, prevention of necrosis and necroptosis pathways using their specific inhibitors could enhance growth/differentiation factor-9 expression, improve survivability as well as the meiotic competency of oocytes, and prevent decline of reproductive potential in several mammalian species and early onset of menopause in women. This study updates the information and focuses on the possible involvement of necrosis and necroptosis in germ cell depletion from the mammalian ovary.     

Structure-activity relationship study of a novel necroptosis inhibitor, necrostatin-7

Necroptosis is a regulated caspase-independent cell death mechanism characterized by morphological features resembling non-regulated necrosis. Necrotatin-7 (Nec-7), a novel potent small-molecule inhibitor of necroptosis, is structurally distinct from previously described necrostatins (Nec-1, Nec-3, Nec-4 and Nec-5). Here, we describe a series of structural modifications and the structure-activity relationship (SAR) of the Nec-7 series for inhibiting necroptosis.